Additional file 1: Table S1. of Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients

MLA

Chondrou, Vasiliki, et al. Additional File 1: Table S1. of Whole Transcriptome Analysis of Human Erythropoietic Cells during Ontogenesis Suggests a Role of VEGFA Gene as Modulator of Fetal Hemoglobin and Pharmacogenomic Biomarker of Treatment Response to Hydroxyurea in β-Type Hemoglobinopathy Patients. Jan. 2017. EBSCOhost, https://doi.org/10.6084/m9.figshare.c.3911650_d1.v1.

APA

Chondrou, V., Kolovos, P., Sgourou, A., Kourakli, A., Pavlidaki, A., Vlasia Kastrinou, John, A., Argiris Symeonidis, Ali, B., Papachatzopoulou, A., Katsila, T., & Patrinos, G. (2017). Additional file 1: Table S1. of Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients. https://doi.org/10.6084/m9.figshare.c.3911650_d1.v1

Chicago

Chondrou, Vasiliki, Petros Kolovos, Argyro Sgourou, Alexandra Kourakli, Alexia Pavlidaki, Vlasia Kastrinou, Anne John, et al. 2017. “Additional File 1: Table S1. of Whole Transcriptome Analysis of Human Erythropoietic Cells during Ontogenesis Suggests a Role of VEGFA Gene as Modulator of Fetal Hemoglobin and Pharmacogenomic Biomarker of Treatment Response to Hydroxyurea in β-Type Hemoglobinopathy Patients,” January. doi:10.6084/m9.figshare.c.3911650_d1.v1.